A Study to Assess safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants with Diabetes
- Conditions
- Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications
- Registration Number
- CTRI/2020/07/026539
- Lead Sponsor
- Johnson and Johnson Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 276
Participant willing to adhere to diet and exercise regimen as recommended by the investigator
- Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on diet and exercise, who in investigatorâ??s opinion are eligible to receive study drug as per prescribing information along with standard care for management of T2DM
- Women must be postmenopausal, defined as greater than 45 years of age with amenorrhea for at least 18 months, or greater 45 years of age with amenorrhea for at least 6 months and less than 18 months and a serum follicle stimulating hormone (FSH) level greater than 40 International Units Per Liter (IU/L), or surgically sterile (have had a hysterectomy or
bilateral oophorectomy, tubal occlusion), or otherwise be incapable of pregnancy, or sexually active and practicing a highly effective method of birth control, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, tubal ligation, intrauterine device, double-barrier method (example, condoms, diaphragm, or
cervical cap with spermicidal foam, cream, or gel), or male partner sterilization, and consistent with local regulations regarding use of birth control methods for participant participating in clinical studies, for the duration of their participation in the study, or not sexually active
- Women of childbearing potential, regardless of age must have a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and negative UPT at baseline (predose, Day 1)
- Treatment naive participants or participants on stable antihyperglycemic agent (AHA) therapy (for at least 12 weeks before screening) and have a screening visit Glycosylated Haemoglobin (HbA1c) of greater than or equal to 7.0 percent (%) and less than or equal to 10.0 %
- History of liver or renal insufficiency (estimated creatinine clearance below 45 milliliter per minute [mL/min]); significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Known allergies, hypersensitivity, or intolerance to Canagliflozin, Metformin or Canagliflozin plus metformin hydrochloride immediate release (IR) Fixed Dose combination (FDC) or its excipients
- Use of any other sodium glucose cotransporter 2 (SGLT2) inhibitor (dapagliflozin or empagliflozin) within 12 weeks before the screening visit
- If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after last dose of study medication; or intending to donate ova during such time period
- History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or betaâ??cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability <br/ ><br> <br/ ><br>2. Percentage of Participants with Unexpected AE or Adverse Drug Reactions as a Measure of Safety and Tolerability <br/ ><br>Timepoint: 24 Weeks
- Secondary Outcome Measures
Name Time Method Percent Change From Baseline in Glycosylated Haemoglobin (HbA1c)Timepoint: Baseline, Week 12, Week 24